Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?

Related Experiment Video

Updated: May 21, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Daniel Crona1, Federico Innocenti

  • 1Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, USA.

Biomarkers in Medicine
|June 27, 2012
PubMed

Insights

Pharmacogenetics helps predict cancer drug reactions, guiding personalized dosing and improving treatment efficacy. Understanding germline variants is key to integrating these markers into clinical practice for better patient outcomes.

Area of Science:

  • Oncology
  • Pharmacogenetics
  • Genomics

Background:

  • Cancer therapies, including chemotherapy and targeted agents, frequently cause adverse drug reactions.
  • Adverse drug reactions can significantly impact treatment efficacy and patient outcomes.
  • Pharmacogenetics offers a potential solution for predicting and mitigating these reactions.

Purpose of the Study:

  • To review validated germline variant-toxicity relationships in cancer treatment.
  • To provide examples of how germline variants influence dosing, survival, and efficacy.
  • To explore barriers to the routine clinical integration of pharmacogenetic markers.

Main Methods:

  • Literature review of pharmacogenetic studies in cancer treatment.
  • Analysis of validated germline variant-toxicity relationships.
  • Examination of clinical case studies demonstrating pharmacogenetic impact on outcomes.

Main Results:

  • Several germline variants have been validated for predicting toxicity and influencing treatment outcomes.
  • Examples exist where pharmacogenetic information has guided dosing strategies and improved survival.
  • The clinical integration of pharmacogenetic markers faces challenges despite demonstrated utility.

Conclusions:

  • Pharmacogenetic prediction of adverse drug reactions is crucial for optimizing cancer therapy.
  • Validated germline variants can inform personalized dosing and improve treatment efficacy.
  • Further efforts are needed to overcome barriers and facilitate routine clinical adoption of pharmacogenetics.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids05:39

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Published on: April 5, 2024

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...